RxDoctor Payments Data

John Wofford, MD

Dermatopathology · Dallas, TXNPI 1245596451

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 393 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 24.2% of the total.

$10,691in general payments, 2019–2025

Across 393 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$1K
  • Amgen$900
  • Johnson & Johnson$823
  • Regeneron Healthcare Solutions, Inc.$635
  • LEO Pharma Inc.$603
  • plus $4K from 29 others

What the payments were for

  • Speaking & faculty fees$2082%
  • Food & beverage$10,27996%
  • Education$2032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,691 in reported general payments places this provider in the 80th percentile of 54 dermatopathology providers in Texas.

See all dermatopathology providers in Texas

Medicare billing

Part B allowed, 2024
$1,237,633
Medicare patients
7,529
Services billed
18,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$253,807
Taltz AutoinjectorIxekizumab16$111,993
Clobetasol Propionate47$1,700
Doxycycline Hyclate35$1,025
Triamcinolone Acetonide89$990
Ketoconazole63$988
Mometasone Furoate55$889
Dutasteride25$746
Desonide11$504
Minoxidil46$497
Clindamycin Phosphate13$462
ValacyclovirValacyclovir Hcl15$343
Glycopyrrolate12$304

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →